NBIX:NSD-Neurocrine Biosciences Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 88.38

Change

+3.78 (+4.47)%

Market Cap

USD 8.27B

Volume

0.80M

Avg Analyst Target

USD 113.12 (+27.99%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Neurocrine Biosciences Inc (NBIX) Stock Analysis:
Based on the Neurocrine Biosciences Inc stock forecasts from 12 analysts, the average analyst target price for Neurocrine Biosciences Inc is USD 113.12 over the next 12 months. Neurocrine Biosciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Neurocrine Biosciences Inc is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, Neurocrine Biosciences Inc’s stock price was USD 88.38. Neurocrine Biosciences Inc’s stock price has changed by +4.04% over the past week, -5.74% over the past month and -8.50% over the last year.

About

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical ...Read More

Company Website : https://www.neurocrine.com

Address : 12780 El Camino Real, San Diego, CA, United States, 92130

Employees : 1,100

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.70

52 Week High : 108.02

Short Ratio : 5.72

52 Week Low : 71.88

Shorted Shares : 4,318,858

200 Day Moving Average : 89.85

Shorted Shares Previous Month : 3,508,284

50 Day Moving Average : 91.47

Shares Held By Insiders : 1.34%

Short Percentage : 4.22%

Shares Held by Institutions : 96.78%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-25 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

 USD8.59B 30.73 11.86
APHA Tilray, Inc

N/A

 USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

 USD6.24B N/A N/A
ITCI Intra-Cellular Therapies Inc

-0.29 (-0.51%)

 USD5.51B N/A N/A
PCRX Pacira BioSciences Inc

-0.42 (-0.69%)

 USD2.87B 75.22 27.19
TLRY Tilray Inc

+0.16 (+3.76%)

 USD2.23B 46.77 N/A
CGC Canopy Growth Corporation

+0.27 (+5.67%)

 USD2.07B N/A N/A
IRWD Ironwood Pharmaceuticals Inc

N/A

 USD1.75B 3.69 6.95
AMPH Amphastar Pharmaceuticals Inc

+2.78 (+8.19%)

 USD1.70B 21.47 11.51
HCM HUTCHMED (China) Limited

+0.24 (+2.79%)

 USD1.49B 17.69 N/A

ETFs Containing NBIX

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.77% 86% B 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.77% 86% B 91% A-
Trailing 12 Months  
Capital Gain -8.23% 85% B 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.23% 85% B 62% D-
Trailing 5 Years  
Capital Gain 91.22% 83% B 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 91.22% 83% B 79% C+
Average Annual (5 Year Horizon)  
Capital Gain 13.84% 71% C- 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.84% 71% C- 66% D
Risk Return Profile  
Volatility (Standard Deviation) 39.83% 59% F 38% F
Risk Adjusted Return 34.76% 84% B 63% D
Market Capitalization 8.27B 100% A+ 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 118.48 8% F 9% F
Price/Book Ratio 5.92 20% F 14% F
Price / Cash Flow Ratio 32.23 6% F 9% F
EV/EBITDA 62.27 14% F 10% F
Management Effectiveness  
Return on Equity 5.50% 84% B 57% F
Return on Invested Capital 5.75% 83% B 64% D
Return on Assets 5.62% 90% A- 82% B-
Debt to Equity Ratio 24.39% 60% D- 57% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 5.72 39% F 28% F
Short Percent 4.22% 64% D 39% F
Beta 0.70 78% C+ 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.